top of page

ABOUT US

Chimeric are pioneers in cell therapy

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. 


Our world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of todays most innovative solutions, and  has shown a consistent ability to deliver on its objectives.


Chimeric's diversified portfolio includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies, with assets being developed across multiple different disease areas in oncology with 3 clinical stage programs.

We currently have 4 clinical trials running in humans.

CHIMERIC 03.png

OUR VALUES

Relentless patient focus

We exist to create a better future for patients with cancer. We know that they are waiting, and & that we must be relentless in pursuit of our mission.

Uncompromising integrity

We committed to choosing what is right – not what is easy – for our patients, stakeholders and employees. We are transparent and take responsibility for our actions,.

Innovation with purpose

We embrace and harness innovation in pursuit of our mission. Our belief in better is a postitively mix  of optimism, curiousity & strategic insight. If there is a better way, we’ll find it.

Drive for Performance

We ground ourselves in science, engage with passion and make excellence our habit, not our goal. We go beyond teh call of duty and embrace the urgency of our mission.

Community Collaboration

We speak openly, give and earn trust daily, and listen to learn. We are accountable to each other for successes and failures, and never take ourselves too seriously.

OUR VISION

A world where all patients with advanced cancer receive transformative therapies

OUR MISSION

To develop and commercialise novel cell therapies for cancer patients

Want to know more?

Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.

bottom of page